AstraZeneca

What AstraZeneca does

AstraZeneca PLC is a global pharmaceutical company headquartered in Cambridge, UK, formed in 1999 through the merger of Swedish Astra AB and UK-based Zeneca Group PLC. The company discovers, develops, manufactures, and markets prescription medicines across four primary therapeutic areas: oncology, cardiometabolic and kidney disease, rare disease (via the Alexion division acquired in 2021 for $39B), and respiratory and immunology. AstraZeneca generated $60.4 billion in revenue with a 17.2% net margin and is publicly listed on both the London Stock Exchange and New York Stock Exchange under ticker AZN, with the NYSE transfer in February 2026 representing the largest market capitalization transfer in the exchange's 234-year history.

AstraZeneca's product portfolio centers on a proprietary antibody-drug conjugate (ADC) platform co-developed with Daiichi Sankyo, including Enhertu (trastuzumab deruxtecan, approved as the first tumor-agnostic HER2-directed therapy in the EU) and Datroway (datopotamab deruxtecan for triple-negative breast cancer). The oncology franchise spans targeted therapies (Truqap for PTEN-deficient prostate cancer), immunotherapies (Imfinzi, Imjudo), and cell therapies (via Neogene Therapeutics acquisition). Rare disease is anchored by Alexion's C5 complement inhibitor Ultomiris (Priority Review for IgA nephropathy) and Strensiq. The cardiometabolic pipeline includes the oral GLP-1 elecoglipron (Phase III), SGLT2 inhibitor Farxiga, and first-in-class aldosterone synthase inhibitor Baxdrostat. AstraZeneca operates globally across 13+ countries with US headquarters in Gaithersburg and has committed RMB 100 billion in China investment by 2030.

AstraZeneca monetizes through pharmaceutical product sales distributed via wholesale, hospital, and specialty pharmacy channels, with secondary revenue from drug licensing arrangements (including milestone payments with Daiichi Sankyo) and debt issuance through AstraZeneca Finance LLC ($2B three-tranche bond offering priced February 2026). The company deploys AI across drug discovery (Tempus AI partnership for Phase 3 trial prediction, Modella AI acquisition, internal QCS algorithm for biomarker scoring), maintains active M&A (Gracell, Fusion Pharma, Amolyt, Icosavax, CinCor, EsoBiotec, SixPeaks Bio totaling $10B+ since 2023), and pursues companion diagnostic integrations (Roche VENTANA PTEN for Truqap). Management has guided to $80B annual sales by 2030 with 20 planned drug launches, positioning the company among the top 10 in Gartner's 2026 Global Supply Chain ranking.

Name

AstraZeneca

Legal name

AstraZeneca PLC

Website

https://astrazeneca.com

Company type

Public

Founded year

1999

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

AstraZeneca is a global pharmaceutical company that develops and markets oncology, cardiometabolic, rare disease, and respiratory prescription medicines, including ADC therapies (Enhertu, Datroway) and oral GLP-1 (elecoglipron), serving patients, healthcare providers, and payers across 13+ countries.

Ownership category

akta.pro rank

Product category

Prescription Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industry

Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)

Keywords

• Prescription pharmaceuticals
• Oncology therapeutics
• Rare disease drugs
• Antibody drug conjugates
• Cardiometabolic medicines

Headquarters

HQ city

Cambridge

HQ country

United Kingdom

HQ region

Europe

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Marketing or Sales, Supply Chain, Operations, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Revenue primarily from global sales of prescription pharmaceuticals across oncology, cardiovascular, respiratory, and rare disease therapeutic areas. Reported $60.4 billion revenue with 17.2% net margin and 19% revenue growth to $12.68 billion in Q1.
2. Drug Licensing and Royalties: Revenue from licensing arrangements including collaboration milestones with Daiichi Sankyo on Enhertu and Datroway. $25 million milestone payment due from AstraZeneca to Daiichi Sankyo for EU Enhertu approval.
3. Bond Offerings: Capital raising through bond issuances. Priced $2 billion three-tranche global bond offering in February 2026 and €1.4 billion bond offering in July 2024 through AstraZeneca Finance LLC subsidiary.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

AstraZeneca is a global biopharmaceutical company that discovers, develops, manufactures, and commercializes prescription medicines across oncology, cardiovascular/renal/metabolic, respiratory and immunology, and rare disease therapeutic areas. Its commercial portfolio includes antibody-drug conjugates (Enhertu, Datroway), immunotherapy (Imfinzi, Imjudo), targeted therapies (Truqap, Camizestrant), complement inhibitors (Ultomiris, Strensiq), and oral small molecules (Elecoglipron, Baxdrostat). Revenue is generated primarily through global product sales of branded pharmaceuticals distributed via wholesalers, hospitals, specialty pharmacies, and payer reimbursement channels.

Differentiator

Problem solved

Functional benefit

Brands

• Truqap: Capivasertib - AKT inhibitor approved as first targeted treatment for PTEN-deficient metastatic prostate cancer
• Enhertu
• Datroway
• Ultomiris
• Elecoglipron
• Baxfendy
• Imfinzi
• Beyfortus
• Imjudo

Products and services

• Enhertu (trastuzumab deruxtecan) HER2-directed antibody-drug conjugate co-developed with Daiichi Sankyo for treatment of unresectable or metastatic HER2-positive solid tumors, including biliary tract, bladder, cervical, endometrial, ovarian, pancreatic, lung, and colorectal cancers. Objective response rates of 46.9% to 52.9% across multiple tumor types.
• Datroway (datopotamab deruxtecan) TROP2-directed antibody-drug conjugate co-developed with Daiichi Sankyo for triple-negative breast cancer and other solid tumors, demonstrating 5.0-month improvement in median overall survival (23.7 vs 18.7 months) and 43% reduction in disease progression or death.
• Truqap (capivasertib) AKT inhibitor indicated in combination with abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer; first targeted therapy for this biomarker-defined population. Reduced risk of radiographic disease progression or death by 19% (median PFS 33.2 vs 25.7 months).
• Imfinzi (durvalumab) PD-L1 monoclonal antibody immunotherapy approved for multiple cancer indications including lung, bladder, liver, and biliary tract cancers, used as monotherapy and in combinations such as the STRIDE regimen with Imjudo for hepatocellular carcinoma.
• Ultomiris (ravulizumab)
• Elecoglipron
• Baxfendy (baxdrostat)
• Etcamah (camizestrant)
• Imjudo (tremelimumab) CTLA-4 inhibitor used in the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab) with Imfinzi for first-line treatment of unresectable hepatocellular carcinoma.
• Andexxa (coagulation factor Xa recombinant)
• Beyfortus (nirsevimab)

Quantifiable outcome

• Enhertu achieved objective response rates of 46.9% to 52.9% across multiple solid tumor types in EU approval study
• +4 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability6 records

Feature3 records

Partnerships

14 partnerships are on record, tiered core, major and minor.

• Daiichi SankyocoreStrategic or Co-development Partner · 29 June 2026Co-development and commercialization partnership for Enhertu (trastuzumab deruxtecan) and Datroway (datopotamab deruxtecan) antibody-drug conjugates. AstraZeneca pays $25M milestone for EU Enhertu approval. Daiichi Sankyo recognizes sales in most EU territories. Partnership advancing ADCs across multiple tumor types.
• Alexion (AstraZeneca Rare Disease)coreStrategic or Co-development Partner · 28 June 2026Internal rare disease division presenting MULBERRY Phase III trial data for efzimfotase alfa in pediatric hypophosphatasia and CHESTNUT trial for treatment switching at 12th International Conference on Children's Bone Health.
• YMCA of the USAmajorGTM or Marketing Partner · 25 June 2026Five-year multimillion-dollar partnership at Aspen Ideas: Health conference for cancer education through screening, early detection, and survivorship programs targeting 175,000 people across 75 communities.
• Korea Health Industry Development Institute (KHIDI)minorGTM or Marketing Partner · 23 June 2026Project NOVA partnering sessions between 13 Korean biotechnology firms and AstraZeneca at BIO International Convention for immunology, oncology, and nephrology technologies.
• Weill Cornell MedicinecoreStrategic or Co-development Partner · 19 June 2026Co-chair of ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development, alongside AstraZeneca, bringing together academia, industry, and regulatory agencies.
• AIM ImmunoTechminorStrategic or Co-development Partner · 18 June 2026Phase 2 DURIPANC clinical trial collaboration evaluating Ampligen in combination with AstraZeneca's Imfinzi for metastatic pancreatic cancer. Joint collaboration with Erasmus Medical Center in Netherlands.
• ZERO Prostate CancerminorGTM or Marketing Partner · 15 June 2026Founding partner of 'Blitz the Barriers' initiative to close survival gap in highest-risk communities and save 100,000 lives by 2035, targeting Black men and veterans.
• China Government (Qingdao)majorOthers · 15 June 2026Commitment to invest over RMB 100 billion in China by 2030 announced at 7th Qingdao Multinationals Summit with 357 multinationals from 44 countries.
• Leica BiosystemscoreStrategic or Co-development Partner · 12 June 2026Expanded strategic collaboration to develop AI-powered diagnostic system for TROP2 Normalized Membrane Ratio biomarker in non-small cell lung cancer. Combines AstraZeneca's QCS algorithm with Leica's digital pathology platforms for precision medicine.
• RochecoreTechnology or Integration · 12 June 2026Roche received FDA approval for VENTANA PTEN companion diagnostic test to identify patients eligible for AstraZeneca's Truqap in PTEN-deficient metastatic prostate cancer.
• CSPC Pharmaceutical GroupmajorTechnology or Integration · 11 June 2026AI platform access and preclinical cancer drugs partnership valued at over $5 billion. CSPC provides AI platform access and preclinical assets for cancer drug development.
• Tempus AIcoreTechnology or Integration · 8 June 2026$200 million data licensing and model development partnership leveraging Tempus's oncology data library to build AI models that analyze clinical and laboratory data to improve trial probability predictions.
• CompugenminorStrategic or Co-development Partner · 4 June 2026Licensing partnership for rilvegostomig (TIGIT inhibitor) with milestone-and-royalty economics. Clinical data presented at ASCO across biliary tract, HER2-negative breast, and HER2-positive gastric cancer.
• LuNGS AllianceminorStrategic or Co-development Partner · 1 March 2025Collaboration providing free NGS tests to over 6,600 lung cancer patients across 700 cities in India, alongside oncologists, government hospitals, pharma companies, and startup 4baseCare.

Scale indicators12 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Pfizer: Direct global pharma peer with overlapping oncology, cardiometabolic and rare disease franchises. Both companies are US/EU-headquartered, operate enterprise field sales to hospitals and specialists, and face the same IRA drug-pricing and patent-cliff dynamics.
• Merck & Co. Direct peer with dominant oncology (Keytruda), vaccines and animal health portfolios. Competes head-to-head with Imfinzi in lung cancer and faces similar pipeline diversification needs as Keytruda approaches LOE.
• Roche: Direct peer in oncology ADCs and companion diagnostics; Roche develops the VENTANA PTEN companion diagnostic paired with AZN's Truqap. Both companies are leaders in HER2 oncology (Roche's Herceptin/Kadcyla vs AZN/Daiichi's Enhertu).
• Novartis: Direct peer in oncology, cardiometabolic and rare disease. Novartis's Pluvicto and Kisqali compete in similar tumor types with Enhertu/Datroway, and both companies target IgA nephropathy through complementary complement-pathway mechanisms.
• Eli Lilly: Direct peer entering the obesity market with leading GLP-1 franchise (Mounjaro/Zepbound) against AZN's oral elecoglipron. Both companies pursue AI-enabled drug discovery and compete for cardiometabolic share via SGLT2/GLP-1 mechanisms.
• Bristol-Myers Squibb: Direct peer in immuno-oncology (Opdivo vs Imfinzi) and cardiovascular/hematology. Both companies navigate similar LOE pressures on blockbuster oncology assets and pursue ADC/cell therapy pipeline strategies.
• Johnson & Johnson (Innovative Medicine): Direct peer in oncology, immunology and pulmonary hypertension with Darzalex, Tremfya and related franchises. Competes with AZN's Imfinzi/Imjudo and ultomiris in adjacent indications.
• GSK: Direct UK peer also headquartered near London with oncology, respiratory and HIV franchises. Competes in respiratory (Trelegy vs Symbicort) and oncology, with similar regulatory exposure on UK pricing/NHS reimbursement.
• Sanofi: Direct European peer with oncology, immunology (Dupixent) and rare disease; co-markets Beyfortus (RSV antibody) with AZN. Both target similar specialty care channels and face parallel biosimilar transition dynamics.
• Novo Nordisk: Direct peer in cardiometabolic/obesity with the dominant GLP-1 franchise (Wegovy/Ozempic). Novo is the primary competitor against AZN's elecoglipron in obesity and type 2 diabetes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/astrazeneca
• Facebookfacebook.com/astrazenecacareers
• LinkedInlinkedin.com/company/astrazeneca

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries7 records

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A25 records

Investments54 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AstraZeneca